Brief: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program

Shuttle Pharmaceuticals Holdings

31/10/2023 13:15

Oct 31 (Reuters) - Shuttle Pharmaceuticals Holdings Inc
 SHPH.O :
    * SHUTTLE PHARMA ADVANCES PROSTATE CANCER PREDICTIVE
BIOMARKER
PROGRAM THROUGH EXCLUSIVE LICENSE AGREEMENT
    * SHUTTLE PHARMACEUTICALS HOLDINGS - WILL ALSO SEEK TO
LEVERAGE
ELIGIBILITY TO APPLY FOR PROJECT BRIDGE FUNDING VIA AN NIH PHASE
IIB SBIR MECHANISM

Source text for Eikon:  ID:nPn9mLsCka 
Further company coverage:  SHPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))